- March 23, 2012 - SAN CARLOS, Calif. --
Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will present a pre-conference workshop entitled “Development of Mechanistic Systems Pharmacology Modeling for Insight and Decision Support” on Tuesday, 27 March 2012, as part of the 3rd Annual World PK/PD Summit, March 27 – 29, 2012 in Boston. Dr. Christina Friedrich will present the pre-conference workshop which highlights the development of systems pharmacology models and Rosa’s Model Qualification Method (MQM). The workshop participants will work through a real case study to learn how mechanistic systems pharmacology modeling can improve scientific and program insights and enhance the quality of decision-making throughout the pharmaceutical discovery/development pipeline.
"This event is one of a series of MQM-focused educational activities in 2012. This series of educational workshops and seminars is designed to inform best practices in the field of mechanistic models and enhance decision making." said Dr. Rebecca Baillie, Rosa's Chief Scientist. "Together with the MQM, they bring an excellent quality standard to systems pharmacology modeling.”
Rosa informs our customer's most critical decisions - from preclinical through clinical development - with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/
pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these approaches, Rosa's clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa's staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/
antivirals. For more information, visit http://www.rosaandco.com
The MQM white paper is available at http://www.rosaandco.com/mqmWhitePaperForm.html
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
# # #
Rosa creates robust mathematical models that simulate drug effects and trial outcomes. Modeling and Simulation complement traditional experimental methods, enabling unique insights that streamline drug development and regulatory interactions.